ES2124318T3 - Compuestos azaciclicos. - Google Patents

Compuestos azaciclicos.

Info

Publication number
ES2124318T3
ES2124318T3 ES93917877T ES93917877T ES2124318T3 ES 2124318 T3 ES2124318 T3 ES 2124318T3 ES 93917877 T ES93917877 T ES 93917877T ES 93917877 T ES93917877 T ES 93917877T ES 2124318 T3 ES2124318 T3 ES 2124318T3
Authority
ES
Spain
Prior art keywords
pct
6alkyl
conrarb
conr13c2
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917877T
Other languages
English (en)
Inventor
Eileen Mary Seward
Christopher John Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929216065A external-priority patent/GB9216065D0/en
Priority claimed from GB929216304A external-priority patent/GB9216304D0/en
Priority claimed from GB929224918A external-priority patent/GB9224918D0/en
Priority claimed from GB929226058A external-priority patent/GB9226058D0/en
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2124318T3 publication Critical patent/ES2124318T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LOS COMPUESTOS DE LA FORMULA (I), Y SALES Y PROFARMACOS DE LOS MISMOS, EN DONDE N ES 1, 2 O 3; X REPRESENTA O O S; R1 ES FENILO OPCIONALMENTE SUSTITUIDO; R2 ES ARILO O HETEROARILO; R4 Y R5 SON, INDEPENDIENTEMENTE, H, HALO, ALQUILO C1-6, OXO, CH2ORA, CO2RA O CONRARB; R8 REPRESENTA C(COORA)2, C(CONRARB) O ALQUILO C1-6 SUSTITUIDO POR C( = NRA)NRBNRCCO2RD, CONHNRARB, C(S)NRARB, CONRAALQUILOC1-6R12, CONR13ALQUINILOC2-6, CONR12ALQUENILOC2-6, COCONRARB, CONRAC(NRB)NRCRD, CONR13SO2RA, SO2NR13CORA, CONRAHETEROARILO O CORQ; RA, RB, RC Y RD SON CADA UNO H, ALQUILO C1-6, FENILO O TRIFLUOROMETILO. R12 REPRESENTA ORA, CONRARB O HETEROARILO; R13 REPRESENTA H O ALQUILO C1-6; Y RQ REPRESENTA UN GRUPO (A) DONDE Q REPRESENTA EL RESIDUO DE UN SISTEMA EN ANILLO AZACICLICO O AZABICICLICO NO AROMATICO; SON ANTAGONISTAS DE LA TAQUIQUININA UTILES PARA SU USO EN UNA TERAPIA.
ES93917877T 1992-07-28 1993-07-20 Compuestos azaciclicos. Expired - Lifetime ES2124318T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929216065A GB9216065D0 (en) 1992-07-28 1992-07-28 Therapeutic agents
GB929216304A GB9216304D0 (en) 1992-07-31 1992-07-31 Therapeutic agents
GB929224918A GB9224918D0 (en) 1992-11-27 1992-11-27 Therapeutic agents
GB929226058A GB9226058D0 (en) 1992-12-14 1992-12-14 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2124318T3 true ES2124318T3 (es) 1999-02-01

Family

ID=27450911

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917877T Expired - Lifetime ES2124318T3 (es) 1992-07-28 1993-07-20 Compuestos azaciclicos.

Country Status (9)

Country Link
US (1) US5561130A (es)
EP (1) EP0652866B1 (es)
JP (1) JPH07508993A (es)
AT (1) ATE173725T1 (es)
AU (1) AU675447B2 (es)
CA (1) CA2138650A1 (es)
DE (1) DE69322275T2 (es)
ES (1) ES2124318T3 (es)
WO (1) WO1994002461A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402688D0 (en) * 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
WO2002002461A1 (en) 2000-07-03 2002-01-10 Zakrytoe Aktsionernoe Obschestvo 'ostim' Method for producing nano-sized crystalline hydroxyapatite
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0606985D0 (en) * 2006-04-07 2006-05-17 Merck Sharp & Dohme Therapeutic agents
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (es) 2011-04-21 2015-06-12 Piramal Entpr Ltd
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US11141494B2 (en) 2014-08-09 2021-10-12 Purdue Research Foundation Development of neurokinin-1 receptor-binding agent delivery conjugates
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2922591A1 (de) * 1979-06-02 1980-12-04 Basf Ag Verfahren zur herstellung von pyrazolen
GB8824400D0 (en) * 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
DE3918979A1 (de) * 1989-06-10 1990-12-13 Basf Ag Verfahren zur herstellung von pyrazol und dessen derivaten
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
DE4028393A1 (de) * 1990-09-07 1992-03-12 Basf Ag Verfahren zur herstellung von 3-methylpyrazol
ATE154354T1 (de) * 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
US5459270A (en) * 1991-08-20 1995-10-17 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPH07508993A (ja) 1995-10-05
CA2138650A1 (en) 1994-02-03
WO1994002461A1 (en) 1994-02-03
EP0652866B1 (en) 1998-11-25
ATE173725T1 (de) 1998-12-15
DE69322275D1 (de) 1999-01-07
AU4713993A (en) 1994-02-14
EP0652866A1 (en) 1995-05-17
DE69322275T2 (de) 1999-06-24
US5561130A (en) 1996-10-01
AU675447B2 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
ES2124318T3 (es) Compuestos azaciclicos.
ES2163410T3 (es) Derivados de benzodiazepina.
NZ511394A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ATE163180T1 (de) N-phenylpyrazole als insektizide und akarizide
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
HUT51863A (es)
DK509382A (da) Fremgangsmaade til fremstilling af antifibrinolytisk virksomme forbindelser
NO924783D0 (no) Terapeutiske midler
HUT68299A (en) Preparations containing (s)-(-)-alfa-etil-2-oxo-1-pirrolidine acetamide for the treatment of anxiety
ES2093523T3 (es) Catalizadores quirales y reacciones de epoxidacion catalizadas por los mismos.
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
NO983691L (no) Forbindelser tilh°rende amidiniumfamilien, farmas°ytiske preparater inneholdende disse samt anvendelse derav
ATE172455T1 (de) Herbizide verbindungen
DK0749438T3 (da) Hidtil ukendte silylforbindelser og deres anvendelse
PT689534E (pt) Derivados amida como ligandos de 5-ht1a
DE69026816D1 (de) Bizyklische amino-substituierte verbindungen
IL86723A0 (en) Guanidine-related compounds comprising a tetraphenylborate ion,their preparation and their use
ES2083162T3 (es) Fosfinita-boranos quirales, su preparacion y utilizacion.
DK32287D0 (da) 3-acylaminomethyl-imidazo(1,2-a)pyridinderivater, fremgangsmaade til fremstilling deraf samt laegemiddel indeholdende saadanne derivater
SE8404906L (sv) Fluoralkylerade karbapenemderivat
ES2149216T3 (es) Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos.
GB2273706B (en) Fused isoxazolidine derivatives and their use in pharmaceutical compositions
DK0731801T3 (da) Substituerede aminoaylkylaminopyridiner
DK280883A (da) Organophosphat-derivater, fremgangsmaade til fremstilling deraf samt deres anvendelse som midler til bekaempelse af skadelige organismer
ATE224866T1 (de) Verfahren zur herstellung von halogenierten derivaten des 2-amino oder 2-acetamido trifluormethylbenzols

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652866

Country of ref document: ES